1. Krasner A. Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD-123 in patients with type 1 diabetes. Webcast presented at 74th ADA Scientific Sessions, San Francisco; June 13-14, 2014.
2. Kaye J, Krasner A, Canney L, Pichotta P, Simms P, Krishnarajah J, et al. Novel formulations BIOD-238 and BIOD-250 result in more rapid absorption and declines from peak than Humalog. Poster presented at 74th ADA Scientific Sessions, San Francisco; June 13-14, 2014. Abstract 1028.
3. Anderson G, Alluis B, Meiffren G, Ranson A, Serousa C, Soula O, et al. The ultra-rapid biochaperone insulin lispro shows a faster onset of action and stronger early metabolic effect than insulin lispro alone. Poster presented at 50th EASD Scientific Sessions, Vienna; September 15-19th, 2014. Abstract 934.
4. Efficacy and safety of FIAsp compared to insulin aspart both in combination with insulin detemir in adults with type 1 diabetes (Onset 1). www.clinicaltrials.gov/ct2/show/NCT01831765 . Accessed July 18, 2016.
5. Hoevelmann U. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of BioChaperone Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes. Poster presented at 50th EASD Scientific Sessions, Vienna; September 15-19th, 2014. Poster 074.